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Recent human genetic studies have provided evidences that sporadic or inherited missense mutations in four-
and-a-half LIM domain protein 1 (FHL1), resulting in alterations in FHL1 protein expression, are associated
with rare congenital myopathies, including reducing bodymyopathy and Emery–Dreifussmuscular dystrophy.
However, it remains tobeclarifiedwhethermutations inFHL1causeskeletalmuscle remodelingowing togain-or
loss of FHL1 function. In this study, we used FHL1-null mice lacking global FHL1 expression to evaluate loss-of-
function effects on skeletalmuscle homeostasis. Histological and functional analyses of soleus, tibialis anterior
andsternohyoideusmusclesdemonstratedthatFHL1-nullmicedevelopanage-dependentmyopathyassociated
with myofibrillar and intermyofibrillar (mitochondrial and sarcoplasmic reticulum) disorganization, impaired
muscle oxidative capacity and increased autophagic activity. A longitudinal study established decreased sur-
vival rates inFHL1-nullmice,associatedwithage-dependent impairmentofmusclecontractile functionandasig-
nificantly lowerexercisecapacity.Analysisofprimarymyoblasts isolated fromFHL1-nullmusclesdemonstrated
earlymuscle fiber differentiation andmaturationdefects, which could be rescued by re-expressionof the FHL1A
isoform, highlighting that FHL1A is necessary for proper muscle fiber differentiation and maturation in vitro.
Overall, our data show that loss of FHL1 function leads to myopathy in vivo and suggest that loss of function
of FHL1 may be one of the mechanisms underlying muscle dystrophy in patients with FHL1 mutations.
INTRODUCTION
Four-and-a-half LIM domain protein 1 (FHL1) is a member of
the gene family encoding LIM domain containing proteins
(1,2). A LIM domain is characterized by two conserved
cysteine-rich zinc-finger motifs, which cooperatively bind zinc
atoms to mediate protein–protein interactions. Distinct splice
variants of FHL1 have been reported, namely FHL1A (also
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known as Slim1, KyoT1 or transcript variant 3 in the mouse),
FHL1B (Slimmer, KyoT3 or transcript variant 1) and FHL1C
(KyoT2 or transcript variant 4), which are composed of a half
LIM followed by four, three and two full LIM domains, respect-
ively (3–5). Differential splicing leads to the presence of a
nuclear-addressing sequence and/or RPB-J-binding domain in
the C terminus of FHL1B and FHL1C isoforms. The FHL1A
isoform can also be transcribed from an alternative upstream
start codon, producing a transcript that bears 48 additional
nucleotides or 16 extra amino acids at the N terminus of the
protein (transcript variant 2 in the mouse) (Fig. 1A). Previous
studies demonstrated that FHL1 is ubiquitously expressed and
interactswith a broad rangeof proteins involved inoncogenicity,
cell structure, migration, differentiation and cell signaling
(reviewed in 6).
The reported expression patterns and subcellular locations of
FHL1 (sarcomeric I-band and focal adhesions for FHL1A,
nucleus and cytoplasm for FHL1B and FHL1C) have suggested
an important role for FHL1 in muscle fiber development, func-
tion and homeostasis. Previous studies have demonstrated a cor-
relation between muscle growth and levels of FHL1, and have
suggested that different muscle types, bearing different propor-
tions of oxidative and glycolytic fibers, could express various
levels of FHL1 protein expression (5,7–9). Most importantly,
recent human genetic studies have linked FHL1 missense muta-
tions to rare congenital myopathies, providing additional evi-
dence of an important role for FHL1 in striated muscle
development and disease: in the cases of reducing body myop-
athy (10–12), X-linked myopathy with postural muscle
atrophy (13,14), rigid spine syndrome (15), scapuloperoneal
muscular dystrophy (16) and Emery–Dreifuss muscular dys-
trophy (17), sporadic and inherited FHL1 missense mutations
or deletions were thought to lead to loss of FHL1 protein
levels and function, resulting in muscular dystrophy.
Clinical analyses of skeletalmuscles frompatientswith FHL1
mutations also provided evidence that premature onset and se-
verity of disease correlated with global downregulation of
FHL1 protein levels (13,17), expression of truncated or mutant
forms of FHL1 isoforms (17,18) and accumulation of mena-
dione-nitro blue tetrazolium (NBT) positive ‘reducing bodies’
(10,11). Reducing bodies are thought to be aggresome-like cell
inclusions that incorporate mutant and wild-type (WT) FHL1,
as well as other proteins involved in cell structure, signaling
and ubiquitination (19,20). It was hypothesized that these aggre-
gates could either ‘sequester’ WT proteins away from their
regular function or play a direct cytotoxic effect by impairing
protein turnover and accelerating muscle wasting. Altogether,
these clinical observations suggested that FHL1 mutations
could confer a complex phenotype through non-exclusive
mechanisms of ‘loss of function’ (reduction of FHL1 protein
levels or impairment toprotein partner binding) andmechanisms
of ‘gain of function’ (accumulation of cytotoxic aggregates).
In the present study, we exploited an FHL1-null mousemodel
to evaluate the effects of FHL1 loss of function on skeletal
muscle development and homeostasis. FHL1-null mice were
previously engineered to disrupt FHL1 gene through a LacZ/
Neo knock-in strategy, resulting in global loss of FHL1
expression in all tissues (21). Our data show that loss of FHL1
function is sufficient to cause an age-dependent myopathy,
associated with myofibrillar (sarcomere) and intermyofibrillar
(mitochondria and sarcoplasmic reticulum, SR) compartmental
disorganization. Analyses of primary myoblasts isolated from
FHL1-null muscles also demonstrates early defects in myofiber
differentiation and growth in vitro that could be rescued with res-
toration of the FHL1A isoform. These studies along with the
unique endogenous fiber-type-specific expression pattern of
FHL1Ainhighlyoxidativefibers suggest an importantcorrelation
between FHL1A and skeletal muscle disease pathogenesis in
muscles bearing increased oxidative capacity and suggest that
mechanisms of ‘loss of function’ could be causally related to
the development of muscle dystrophy in patients with FHL1
mutations.
RESULTS
FHL1 expression and localization in WT muscles
To determine FHL1 abundance in adult mouse skeletal muscles,
we first investigated FHL1 mRNA expression levels in various
striated muscles isolated from 4- to 6-week-old Black Swiss
mice and compared them with FHL1 expression in other organs.
Quantitative polymerase chain reaction (qPCR) analysis using a
set of SYBRGreen-based primers recognizing all FHL1 isoforms
(Supplementary Material, Fig. S1) showed ubiquitous expression
of FHL1, with mRNA enrichment in muscles with high oxidative
capacity (soleus, sternohyoideus) when compared with glycolytic
muscles (e.g. tibialis anterior, triceps) (Fig. 1B). High levels of
FHL1 were also detected in kidneys, the olfactory bulb and
lungs. Western blot analysis confirmed protein expression levels,
with oxidative and mixed muscles (soleus, diaphragm, gastrocne-
mius, sternohyoideus) expressinghigher levelsofFHL1compared
with highly glycolytic muscles (tibialis anterior, triceps, biceps,
extensor digitorum longus) (Fig. 1D). qPCR analysis with SYBR
Green-based primers detecting 5′ UTR sequences specific for
FHL1isoforms(SupplementaryMaterial,Fig.S1) further revealed
that FHL1A transcript variant 3 (i.e. Slim1, KyoT1) was the pre-
dominant transcript expressed in adult heart, lungs, kidney and
liver, while adult skeletal muscles predominantly expressed the
FHL1A transcript variant 2 (Fig. 1C). Western blot analysis
using an antibody recognizing the C-terminal end of FHL1 also
identified two distinct FHL1 protein bands at 31 and 33 kDa
(arrow), correlating with the presence of FHL1A transcript var-
iants 2 and 3 in respective muscle types. These data further
suggest that the two distinct FHL1 proteins likely corresponded
to FHL1A transcript variant 2 (33 kDa) and transcript variant
3 (31 kDa) isoforms. FHL1 transcriptional profiling by RNA-
sequencing confirmed predominant expression of FHL1A tran-
script variant 2 (NM_001077362) in WT mouse skeletal muscles
(soleus, tibialis anterior (TA) and diaphragm) and expression
of FHL1A transcript variant 3 (NM_010211) in cardiac tissue
(Supplementary Material, Fig. S3).
A comparative analysis of FHL1 protein expression between
juvenile human gracilis and semitendinosus hamstrings, com-
posed of 60% type-I and 20% type-IIa fibers (22), to
mouse sternohyoideus revealed similarFHL1protein expression
patterns, with two identifiable bands at 31 and 33 kDa, suggest-
ing relevance and conservation of both FHL1A isoforms in
mouse and human skeletal muscles. In the mouse, FHL1B was
expressed at low levels in all tissues, except in the brain where
it constituted up to 15–20% of the total pool of FHL1 mRNA.
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Figure1.FHL1expression inWTmice. (A) FHL1gene structure and splicing isoforms in themouse.TheFHL1gene is situated on theXchromosome in both humans
and rodents. Gene expression leads to the production of at least four protein-coding splicing isoforms in themouse, namely FHL1A transcript variant 3 (FHL1A-Tr3),
FHL1Atranscript variant 2 (FHL1A-Tr2), FHL1BandFHL1C.FHL1A-Tr3andFHL1Cshare the same5′ untranslated region (UTR1),whileFHL1A-Tr2andFHL1B
havedistinct 5′ untranslated regions (UTR2andUTR3). FHL1Bcontains nuclear localization and exporting sequences (NLSandNES) and anRPB-J bindingdomain,
while FHL1C contains only the RPB-J binding domain. (B) Absolute quantization of total FHL1 expression byRT-Quantitative polymerase chain reaction (qPCR) in
adult mouse tissues. Bars (mean+SEM) represent the number ofmRNA copies of total FHL1mRNA in each adult tissue. For each single experiment, amplification
valueswerecomparedwith a standardcurvemadeofknownconcentrationsof clonedFHL1cDNAsequences (N ¼ 4–6mice;mean+SEM). (C)Relativepercentage
of FHL1 mRNA isoform expression through various skeletal muscles and other tissues, as measured by primers recognizing different 5′ UTR regions. Of note,
FHL1-Tr3 abundance could also include FHL1C levels, as both isoforms would be amplified by the same set of primers recognizing a shared UTR region and
exon 3 (see Supplementary Material, Fig. S1). (D) Qualitative FHL1 protein expression analysis for various skeletal muscles (two replicates). The antibody
(Aviva, against the C-terminal region of FHL1) detected two separate bands at 31–33 kDa (arrow). FHL1 expression levels for WT triceps muscles (Tri) are
below detection levels after 10 s exposure time, but are revealed at longer exposures. In the lowest panel, the same antibody is used to compare FHL1 expression
levels between mouse sternohyoideus (three replicates) muscle and human gracilis and semitendinosus hamstrings (three patients, in duplicate). Protein load for
the 25–37 kDa ranges is shown for each western blot (Ponceau S staining). (E) Single channel and composite color pictures illustrating nuclear (DAPI), FHL1
(Aviva antibody) and MHC-I immunostaining in FHL1-null (negative control) and WT adult skeletal muscles (scale bar ¼ 40 mm). The yellow arrows indicate
FHL1 nuclear staining. Sol, soleus; Tri, triceps; Brain TL, brain temporal lobe; EDL, extensor digitorum longorum; TA, tibialis anterior; Bi, biceps; Dia, diaphragm;
Ga, gastrocnemius; Brain OB, brain olfactory bulb; Ste, sternohyoideus; Mm, mus musculus; Hs, Homo sapiens.
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qPCR analysis using TaqManwProbe-based primers specific for
FHL1A, FHL1B and FHL1C validated the relatively low abun-
dance of FHL1B and FHL1C mRNA and the enrichment of
FHL1A mRNA in adult mouse soleus muscle (Supplementary
Material, Fig. S1).
Immunohistological analysis performed on cross sections of
mouse sternohyoideus and medial gastrocnemius muscle,
which is a mixed muscle largely composed of fast-twitch
fibers, revealed weaker staining in larger fibers, with significant
subsarcolemmal andmoderately punctuated sarcoplasmic stain-
ing in medium-to-smaller fibers. Strong sarcoplasmic staining
was observed in smaller oxidative type-I fibers, expressing
myosin heavy chain I (MHC-I) (Fig. 1E). Cross-sectional ana-
lysis also suggested nuclear localization (yellow arrows). This
fiber-specific pattern of expression supports mRNA and
protein expression analyses showing increasedFHL1expression
in oxidative fibers and establishes a correlation between muscle
oxidative capacity and FHL1 expression levels in the mouse.
Survival rates in FHL1-null mice
To evaluate the effects of global FHL1deficiency on animal life-
span, we performed a 21-month survival study on FHL1-null
mice and their WT littermates (Fig. 2A). Our results showed
that both FHL1-null hemizygote (y/2) males and homozygote
(2/2) females (on 100% Black Swiss background) exhibited
a decline in survival rates 6 and 12 months of age, respect-
ively, when compared with WT (y/+, +/+) and heterozygote
(+/2) littermate controls, suggesting that FHL1 is essential
for survival.
Overt signs of muscle remodeling in FHL1-null mice
To assess whether the increased mortality in FHL1-null mice
was associated with muscle structural damage, we performed
histological analysis on muscle sections from 1- to 5–
6-month-old FHL1-null hemizygote (y/2) versus age-matched
WT littermates (y/+). Striking visual changes were observed at
the level of the sternohyoideusmuscle, which belongs to a group
of upper airway dilator muscles (23). This muscle exhibited
overt signs of muscle thinning (Fig. 2B) and dystrophy
(Fig. 2C) in FHL1-null mice. This was observed with 100%
penetrance at the age of 1 month. Electrophoretic separation of
MHC isoforms indicated significant loss of MHC type-I
(250%), type-IIa (230%) and type-IIb (215%) fiber content
and an increase in type-IIx content (+100%) (Supplementary
Material, Fig. S4). Significant histopathological changes were
also observed in 5–6-month-old distal pelvic limb muscles in
FHL1-null mice. These changes included an increased percent-
age of oxidative fibers (staining blue/dark blue for nicotinamide
adenine dinucleotide, NADH) with centralized nuclei, suggest-
ing muscle fiber regeneration in both muscles (black arrows)
(Fig. 2D). In addition, small round and dense structures staining
dark blue with the nicotinamide adenine dinucleotide tetrazo-
lium reductase (NADH-TR) reaction (black arrows) were
detected in both FHL1-null TA and soleus muscles (Fig. 2E).
An age-dependent fiber-type switch was observed in the glyco-
lytic TA, but not in the oxidative soleus, as evidenced by an
2 fold increase in oxidative type-I fiber content, likely reflect-
ing regeneration of oxidativefiber content in theTA, followedby
an 8% decrease in glycolytic type-IIb fibers at the age of 5–6
months (SupplementaryMaterial, Fig. S4).Histological analysis
of theFHL1-null diaphragmalso revealedmuscledefects similar
to FHL1-null soleus muscle and distinct from controls (data not
shown).
Myofibrillar and intermyofibrillar disorganization
in FHL1-null muscles
Ultrastructural analysis by transmission electron microscopy
(TEM) highlighted the extensive myofibrillar and SR disarray
in the sternohyoideus muscle of FHL1-null mice as early as 1
month of age (Fig. 3A). Age-dependent structural changes
were also observed in pelvic limbs muscles of FHL1-null
mice. They included sarcomeric Z-line streaming and
regions of progressive myofibrillar degeneration in the
soleus muscle (Fig. 3A), as well as SR enlargement and
branching in both soleus and TA muscles, with accumulation
of electron-dense SR glycogen particles in the TA (Fig. 3B).
Mitochondria presenting uneven morphology was a promin-
ent feature observed in the sternohyoideus, soleus and TA
muscles (Fig. 3A and B). Altogether, these data suggest that
loss of FHL1 function is sufficient to cause muscle fiber re-
modeling associated with myofibrillar and intermyofibrillar
disorganization. These data also suggest that oxidative and
glycolytic muscle types, which express different endogenous
levels of FHL1, respond differently in terms of disease in the
absence of FHL1.
Differential protein expression profiling in FHL1-null
soleus and TA muscles
To evaluate global protein expression patterns associated with
myofibrillar and intermyofibrillar skeletalmuscledefectsobserved
in FHL1-null oxidative soleus and glycolytic TAmuscles,we per-
formed a rigorous label free protein quantification using liquid
chromatography–tandem mass spectrometry (LC–MS/MS) on
protein extracts from 5- to 6-month-old FHL1-null soleus and
TA muscles and compared them with age-matched WT controls
(n¼ 4 for each muscle extract and each sample run two separate
times). Statistical analysis using IdentiQuantXLTM software
(24) indicated90and72uniquemouseproteinsbeingdifferentially
regulated in FHL1-null soleus and TA muscles, respectively
(Supplementary Material, Tables S1 and S2). In the soleus,
85/90 identified proteins were found to be downregulated, while
71/72 proteins identified in the TA were upregulated. The list of
differentiallyexpressedproteinswasexaminedforoverrepresenta-
tion of gene ontology (GO) annotation classes using the Database
for Annotation, Visualization and Integrated Discovery (DAVID
v6.7) tool (available at http://david.abcc.ncifcrf.gov/). Of note,
biological processes (GOTERM_BP_FAT) like ‘generation of
precursormetabolites andenergy’, ‘oxidative reduction’, ‘electron
transport chain’ and ‘ion transport’ achieved statistically signifi-
cant EASE score (P, 0.001) among the regulated proteins in
both FHL1-null soleus and TA muscles, independent of their ex-
pression levels. These data suggest a downregulation (soleus) or
increased abundance (TA) of proteins associated with mitochon-
drial respiratory activity in FHL1-null muscles. Upregulation of
mitochondrial protein content in FHL1-null TA muscle could
reflect increased oxidative fiber content in this muscle as
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Figure 2. FHL1-null survival rate and muscle remodeling. (A) Survival plot of WT and FHL1-null mice. Survival expressed as percentage of the total number of
animals per group surviving at observational time (in months). Plots show survival rates for WT (y/+) and hemizygote (y/2) FHL1-null males, as well as WT
(+/+), heterozygote (+/2) and homozygote (2/2) FHL1-null females. In brackets are expressed, the ratios between the numbers of surviving animals at the
end of the study over their initial number. (B) Surgical dissection of the supra- and infrahyoid musculature of the mouse and the detailed localization of the sterno-
hyoideusmuscle (Ste) in aWT and FHL1-null mouse. This thinmuscle sheet (arrow) extends invariably from the hyoid bone and enters the tongue laterally, between
the masseter and stylohyoideus muscles. In FHL1-null mice, the thinning of the sternohyoideus muscle visually exposes the trachea underneath. (C) Fresh frozen
muscle cross-sections (8 mm) from the sternohyoideus muscle of 1-month-old WT and FHL1-null mice stained with hematoxylin and eosin (H&E) and modified
Gomori trichrome (GO-TRI) stains. ComparedwithWTmuscle, a marked variability in myofiber size, presence of atrophic and hypertrophic fibers, and endomysial
fibrosis in areas of atrophic fibers was observed in FHL1-null mice. (D) Fresh frozenmuscle sections (8 mm) from the gastrocnemiusmuscle of 5-month-oldWT and
FHL1-nullmousewere stained forH&EandNADH-TR.Arrows indicate singlefibers (WT)and topological regions (FHL1-null) containingcentralizednuclei.Quan-
titation of central nucleation inWT and FHL1-null gastrocnemius: the number of muscle fibers with central nuclei is represented as % of the total number of muscle
fibers analyzed (∗P , 0.01; one-wayANOVA;N ¼ 16 fields/4 animals per group). (E)Magnifications stained for NADH-TR andGomori trichrome stain (GO-TRI)
indicating punctuated areas of densely accumulated and uneven distributed mitochondria in FHL1-null muscle (black arrows).
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Figure3.Myofibrillarand intermyofibrillardefects inFHL1-nullmuscles. (A)Transmissionelectronmicrographs (TEMs)of longitudinally sectionedsternohyoideus
(upperpanels) and soleus (lowerpanels)muscles fromWTandFHL1-null (null)mice.Sternohyoideus (Ste)muscle showedextensive sarcomere (S) and sarcoplasmic
reticulum (SR) disarray, while soleus (Sol) muscle presented focal areas of Z-line streaming (horizontal arrow), as well as subsarcolemmal and intermyofibrillar ac-
cumulation of mitochondria (Mt), associated with areas of progressive sarcomere degeneration (asterisks). (B) TEM of longitudinally sectioned soleus (left panels)
andTA (right panels)muscles fromWTandFHL1-null (null)mice, indicatingmitochondrial (Mt) and sarcoplasmic reticulum (SR) remodeling in FHL1-null tissues.
(C) Citrate synthase (CS) enzyme activity in soleus (Sol), tibialis anterior (TA) and sternohyoideus (Ste)muscles of 1- and 5–6-month-oldWT and FHL1-null (null)
mice. Values presented as mean+SEM, N ¼ 5–8. Statistical analysis by two-way ANOVA (for genotype and age differences) showed an age- and genotype-
dependent decrease in CS activity in FHL1-null soleus (#P, 0.01), as well as a genotype-dependent (but age-independent) decrease in CS activity in FHL1-null
sternohyoideus (∗P , 0.01).
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demonstrated by electrophoretic separation of MHC isoforms
(SupplementaryMaterial, Fig. S4). The cellular content categories
‘mitochondrion’, ‘mitochondrial part’ and ‘mitochondrial inner
membrane’ (GOTERM_CC_FAT) confirmed overrepresentation
and differential changes of mitochondrial organelle-related cat-
egories in these muscles (EASE score, P, 0.001).
Decreased citrate synthase activity in FHL1-null muscles
To assess whether observed mitochondrial defects in FHL1-null
mice were associated with alterations inmuscle aerobic capacity,
citrate synthase (CS) activity measurements were performed on
mitochondrial preparations isolated from 1- to 5–6-month-old
FHL1-null soleus, sternohyoideus andTAmuscles and compared
with WT littermate controls. Our data demonstrate a decrease in
CS activity in FHL1-null sternohyoideus and soleus muscles,
but not in theTA, suggesting a reduction in skeletalmuscle oxida-
tive enzyme activity and mitochondrial content in muscles with
higher aerobic capacity (Fig. 3C).
FHL1 localizes to mitochondria in muscle fibers
Given the prominent mitochondrial defects in FHL1-null
muscles, we sought to assess whether FHL1 could play a direct
role in mitochondrial remodeling. Immunohistological analysis
was performed on longitudinal and transversal sections of the
soleus muscle from 4- to 6-week-old WT Black Swiss mice.
Our data showed that FHL1 could partially co-localizewithmito-
chondrial protein markers within sarcomeric (transverse) and
intersarcomeric (longitudinal) regions (white arrows) of soleus
muscle (Fig. 4A). Cross-sectional analysis revealed significant
subsarcolemmal and punctuated sarcoplasmic co-localization
(white arrows). Diffused and pronounced sarcoplasmic and
nuclear co-stainingwas also observed in smaller cells reminiscent
of satellite cells surroundingmaturemuscle fibers (yellowarrow).
We further showed through cellular sub-fractionation studies
that FHL1 co-segregated in a mitochondrial-enriched fraction
obtained from skeletal muscle tissue, suggesting a potential role
forFHL1as regulator ofmitochondrial homeostasis andoxidative
capacity (Supplementary Material, Fig. S5).
Figure 4. FHL1 co-localizes with mitochondrial markers in vivo and in vitro. (A) Immunohistochemistry of longitudinal and transversal cryosections (8 mm) from
1-month-old WT mouse soleus muscle stained with DAPI (nucleus), FHL1 (Aviva antibody) and mitochondrial inner-membrane marker NADH dehydrogenase
(ubiquinone) 1 alpha subcomplex, 9 (NDUFA9). On longitudinal sections, the white arrows indicate FHL1 and NDUFA9 co-localization at transversal and longitu-
dinal sarcomeric regions occupied bymitochondria.On transversal sections, the same arrows indicate FHL1 andmitochondria co-localization at subsarcolemmal and
punctuated regions within the sarcoplasm. (B) FHL1 and mitochondria partially co-localize (white arrows) within the sarcoplasmic regions of myoblasts (MB) and
differentiating myotubes (MT) 3 days after serum withdrawal in vitro.
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No reducing bodies but increased autophagic activity
in FHL1-null muscles
Histological analysis of soleus, TA and sternohyoideus muscles
in5- to6-month-oldFHL1-nullmice also showednegative stain-
ing for menadione-NBT reducing bodies and for congophilic
inclusions (Supplementary Material, Fig. S6). Ultra structural
TEM analysis further confirmed absence of electron-dense
sarcoplasmic structures previously associated with
FHL1-dependent reducing bodies (10,11). Instead, accumula-
tion of intersarcomeric and juxtanuclear inclusion bodies remin-
iscent of autophagosomes or autolysosomes with accumulation
of lipofuscin-like material was evident in soleus and TA
muscles isolated from 5- to 6-month-old FHL1-null mice
(Fig. 5A). To assess whether these membrane-delimited struc-
tures were associated with increased autophagy, we monitored
LC3 conjugation by western blot analysis. Although lipid-
conjugated LC3-II levels were comparable at baseline, a 6-h
fasting protocol was sufficient to stimulate a marked increase
in lipid-conjugated LC3-II levels in 5- to 6-month-old
FHL1-null soleus, TA and sternohyoideus muscles when com-
pared with age-matched WT (Fig. 5B). These data suggest that
FHL1-null skeletal muscles have increased susceptibility to
autophagic activity after a mild fasting protocol.
Figure 5. Enhanced autophagic activity in FHL1-null muscles. (A) TEMs of longitudinally sectioned soleus (left panels) and TA (right panels) muscles from
5–6-month-old FHL1-null (null) mice, indicating accumulation of autophagosome- or autolysosome-like structures (arrows) around the nucleus (Nu) and at inter-
sarcomeric regions in FHL1-nullmice. These structureswere not observed inWTmuscles (data not shown).Mt, mitochondria; SR, sarcoplasmic reticulum; S, sarco-
mere. (B)Western blot analysis of LC3 in 5–6-month-oldWTandFHL1-null sternohyoideus (Ste), soleus (Sol) and tibialis anterior (TA)muscles, at baseline (i.e. fed
conditions) and after a 6-h fasting protocol. Statistical analysis by two-wayANOVA (for genotype and treatment) indicated that LC3-II/LC3-I ratio was significantly
increased in FHL1-null muscles after 6 h fasting (#P, 0.01). Values presented as mean+SEM, N ¼ 3 mice per group.
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Impaired force production and muscle fatigue
in FHL1-null mice
To evaluate whether the morphological and molecular defects
observed in FHL1-null muscles were associated with muscle
dysfunction, an isometric stress analysis of the fast-twitch 5th
toe extensor digitorum longus (EDL) muscle was performed
in 1- and 5–6-month-old FHL1-null males and age-matched
WT littermates. Our data showed an age-dependent decrease
in average isometric stress (i.e. force normalized byphysiologic-
al cross-sectional area, PCSA) and EDL fiber length, associated
with an age-independent increase inmuscle PCSA in FHL1-null
mice (Fig. 6). These data demonstrate impaired performance
during skeletal muscle contraction in 5–6-month-old FHL1
null, causing susceptibility to contraction-induced injury, as pre-
viously suggested (25). Similar to the glycolytic TAmuscle, the
EDL showed age-dependent fiber-type switch, as evidenced by
an 2-fold increase in oxidative type-I and type-IIa fiber
content, followed by an 10% decrease in glycolytic type-IIb
fibers at the age of 5–6 months (Supplementary Material,
Fig. S4). A fatigue exercise protocol performed on treadmills
by 1-year-old mice showed that FHL1-null mice were prone to
globalmuscular fatigue, by dropping out of the exercise protocol
earlier (18+ 2.1 min versus 27+ 2.5 min, n ¼ 4, P ¼ 0.019)
and at lower speed (0.17+0.015 m/s versus 0.26+0.020 m/s,
n ¼ 4, P ¼ 0.008) when compared with WT littermates.
Loss of FHL1 function impairs myoblasts homeostasis
and muscle fiber maturation in vitro
Toevaluate thecellular roleofFHL1inskeletalmusclehomeosta-
sis, we isolated primary myoblasts from 4- to 5-week-old
WT soleus muscles and characterized FHL1 expression during
differentiation into myotubes. We showed that total FHL1
mRNAwas upregulated duringmyotube differentiation andmat-
uration, suggestive of a role for FHL1 inmuscle development and
maturation. Interestingly, upregulationofFHL1mRNAwasasso-
ciated with an isoform switch from FHL1A transcript variant 3 to
FHL1A transcript variant 2 as well as downregulation of FHL1B
(i.e. transcript variant 1) (Fig. 7A). Similar observations were
found at the protein level (Fig. 7B). Furthermore, assessment of
FHL1 localization in proliferating WT myoblasts and myotubes
(2–5 days old), revealed partial co-localization with mitochon-
drial markers, suggesting close proximity between FHL1 and
mitochondrial organelles during muscle fiber maturation
(Fig. 4B).
To evaluate the early consequences of loss of FHL1 on skel-
etal muscle development and maturation, we compared growth
characteristics of FHL1-null versus WT control myoblasts
from soleus muscles, following in vitro differentiation to myo-
tubes. Loss of FHL1 function resulted in delayed muscle fiber
formation and maturation, as evidenced by decreased number
of forming myotubes (Fig. 7C) and decreased myoblast fusion
indexes 2–5 days following serum withdrawal in FHL1-null
cells (Fig. 7D). These early skeletal muscle growth defects
were associatedwith decreased levels of selectivemitochondrial
electron-transfer protein markers, in both FHL1-null proliferat-
ing myoblasts and differentiating myotubes. These data suggest
that loss of FHL1 impairs myoblasts homeostasis and muscle
fiber formation in vitro. We further showed that restoration of
the muscle-predominant isoform FHL1A transcript variant 2,
but not FHL1B overexpression, was sufficient to rescue the
muscle fiber maturation defects, as evidenced by the increased
myoblast fusion indexes 3–5 days after serum withdrawal
and re-expression of mitochondrial markers equivalent to WT
controls levels (Fig. 7D and E; Supplementary Material,
Figs. S7 and S8). Altogether, these data suggest that early
muscle defects associated with FHL1 are causatively related to
loss of FHL1A transcript variant 2 expression and its role
during differentiation is necessary for muscle fiber maturation
in vitro.
DISCUSSION
In this study, we provide compelling evidence that loss of FHL1
function is sufficient to induce development of a progressive
myopathy associated with myofibrillar and intermyofibrillar
Figure6. Isometric forcegeneration in isolated5th toesof the extensor digitorumlongus (EDL).Bargraphs (mean+SEM)represent the length (A), thePCSA(B), the
average force (C) and the average isometric stress (D) of the fifth toe of isolatedEDLmuscles from1- to 5–6-month-oldWT and FHL1-nullmice. Statistical analysis
by two-wayANOVA(fordifferences ingenotypeandage) indicatedanage- andgenotype-dependentdecrease infiber length (#P , 0.01).The sameanalysis showeda
genotype-dependent (but age-independent) increase in PCSA (∗P, 0.01) and an age-dependent (but genotype-independent) decrease in average force generated
(§P , 0.05). Finally, an age- and genotype-dependent decrease in average isometric stress was measured in FHL1-null EDL (#P , 0.01). N ¼ 4 animals/8
muscles per group.
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Figure 7.FHL1 expression and role inmuscle fiber differentiation in vitro. (A) Absolute quantification of FHL1 isoformexpression byRT-qPCR in proliferatingWT
myoblasts (MB) and differentiatingmyotubes (MT), 5 days (5D) and 10 days (10D) after serumwithdrawal (N ¼ 4myoblasts preparations, from four different mice
per group). Bars (mean+SEM) represent the number of mRNA copies of each FHL1 isoform, as indicated in legend of Figure 1. (B) Qualitative (left panel) and
quantitative (right panel) FHL1 protein expression analyses in proliferating myoblasts (MB) and differentiating myotubes (MT), 3 days (3D) and 5 days (5D) post-
serumwithdrawal. The antibody (Aviva) detected two separate bands at 31–33 kDa (arrow), as previously shown in adult muscle tissue (Fig. 1). Quantification and
statistical analysis by two-way ANOVA (for time-course and protein band expression) indicated a switch in FHL1 bands expression during differentiation (#P ,
0.01). The 5–15 kDa rangewas used as a protein loading control for eachwestern blot (Ponceau S staining). (C) Lightmicroscopic images depicting themorphology
of differentiatingmyoblasts 3 dayspost-serumwithdrawal. From left to right,WTmyoblasts naturally elongated and fused to formmyotubes in vitro. This processwas
severely compromised in FHL1-null (null) myoblasts. Permanent transfection of a pCDNA-His vector containing a FHL1A transcript variant 2 (Tr2) cDNAwas suf-
ficient to rescuemyotube formation in FHL1-nullmyoblasts. Transfection of FHL1BcDNAor the empty vector did not have the same effect in FHL1-nullmyoblasts.
(D) Myoblast fusion assay revealed significantly lower fusion indexes in FHL1-null cells and in FHL1-null cells permanently transfected with a pCDNA-His vector
containing a FHL1BcDNAor empty. Transfection of FHL1-nullmyoblastswith a pCDNA-His vector containingFHL1A-Tr2was sufficient to restore fusion indexes
3 days (3D) and 5 days (5D) after serum withdrawal. Statistical analysis performed as pair-wise comparisons (one-way ANOVA) to WT condition at the same time
point (∗P , 0.01, N ¼ 3–5 myoblasts preparations per group, from 3 WT and 3 FHL1-null mice). (E) Western blot detection of mitochondrially encoded NADH
dehydrogenase (ubiquinone) 1 alpha subcomplex, 9 (NDUFA9) and cytochrome c oxidase I (MT-CO1) inWTandFHL1-null proliferatingmyoblasts (MB) andmyo-
tubes (MT), 5 days (5D) post-serumwithdrawal, as well as FHL1-nullmyotubes expressing pCDNA-His FHL1A-Tr2 or FHL1B. For quantification, see Supplemen-
tary Material, Figure S7.
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disorganization in mice. Specifically, we demonstrate that FHL1
deficiency in vivo is associatedwith (i) defects in SR structure and
mitochondrial content, with accumulation of intersarcomeric and
juxtanuclear inclusion bodies and susceptibility to autophagy in
both oxidative and glycolytic muscles; (ii) development of myo-
fibrillar disarray and decreased aerobic activity in muscles that
expressed higher oxidative capacity; (iii) decreased survival
rates, associated with age-dependent impairment of muscle con-
tractile function and lower exercise capacity and (iv) expression
of FHL1A transcript variant 2 is required for proper muscle
fiber differentiation and maturation in vitro.
Skeletal muscle fibers are generally categorized according to
contractile and metabolic properties (26). Two major groups of
fibers are the slow-contracting, highly oxidative type-I fibers
and the fast-contracting type-II fibers, the latter being further
divided according to metabolic/contractile properties into
type-IIa (oxidative and glycolytic), type-IIx (moderately glyco-
lytic) and type-IIb (purely glycolytic). Each of these main fiber
typesbears distinct profileswith regard tocross-sectional dimen-
sions, with type-I fibers having the smallest diameter, type-IIa
being intermediate in size and type-IIb being the largest. Our
study confirms previous observations (7) suggesting that FHL1
is not restricted to a specific fiber type and that FHL1 expression
levels are not distributed equally among all fiber types. Our
expression and localization analyses showed that FHL1 levels
were highest in muscles with an elevated proportion of smaller
oxidative type-I/IIa fibers. That is, FHL1 levels were associated
with the metabolic/oxidative capacity of the muscle rather than
its contractile properties, suggestive of a potential role for
FHL1 as a regulator of muscle aerobic capacity. This hypothesis
was supported by our findings that FHL1 proteins co-localized
and/or co-fractionated with energy-producing mitochondrial
organelles in adult tissue in vivo and in forming myotubes
in vitro. Moreover, FHL1 deficiency in mice caused significant
mitochondrial dysmorphism and mislocalization in all muscles
types, with decreased aerobic capacity and reduced expression
of mitochondrial proteomic markers, such as NDUFA2,
NDUFS2 and COX5A, in muscles with high oxidative capacity
(Fig. 3B; Supplementary Materials, Tables S1 and S2). Finally,
our in vitro data showed that both FHL1-deficient myoblasts
and forming myotubes downregulated mitochondrial protein
markers NDUFA9 and MT-CO1 (also known as COX1),
which are important building blocks of respiratory electron
chain complex I and cytochrome c oxidase subunit I. Levels of
these proteins were restored by re-expressing an FHL1A
isoform, suggesting that progressive skeletalmuscle remodeling
in FHL1-null mice could be closely related to dissipating energy
stores, and that disease pathology and severity could therefore be
associated with intrinsic metabolic defects directly caused by
FHL1A loss of function.
Our study also revealed that FHL1 deficiency was associated
with development of myofibrillar disarray in vivo and decreased
myoblasts fusion and differentiation in vitro. These observations
are consistentwith previous reports identifyingFHL1as a neces-
sary scaffolding protein in sarcomeric assembly and signaling
cascades during muscle fiber maturation and homeostasis
(8,9,21). Interestingly, muscles that presented overt signs of
myofibrillar myopathy in FHL1-null mice were also the ones
that expressed the highest levels of FHL1 under WT conditions
(i.e. sternohyoideus and soleus). This observation suggests
that severity of myofibrillar remodeling could be linked to
FHL1 expression levels under physiological conditions.
Our study showed that the sternohyoideus was the most dys-
trophicmuscle inFHL1-nullmice.Consistentwith its fiber-type
distribution, thismuscle is classified as amoderately fast-twitch
muscle (27) but with high oxidative capacity, as confirmed by
significant levels of type-IIa fibers content and high CS activity.
Importantly, the sternohyoideus belongs to a group of upper
airway dilator muscles that regulate airway patency and
prevent collapse of upper airway following negative pressure
generated during inspiration (28). Abnormal pharyngeal
muscle function andmorphology is frequently observed in clin-
ical cases of Duchennemuscular dystrophy or oculopharyngeal
muscular dystrophy where it causes upper airway occlusion,
dysphagia and obstructive apneas (29,30). Experimentally,
severe sternohyoideus dysfunction and remodeling were also
reported in two other mouse models of muscular dystrophy,
namely the dystrophin-deficient mdx mouse and the merosin-
deficient dy/dy mouse model (31,32), suggesting that this
phenotype is not specific to FHL1 deficiency but may also
reveal that FHL1-linked mechanisms could be affected in
other myopathies. The mechanisms, by which the sternohyoi-
deus degenerates faster than limb muscles in the absence of
FHL1 (or other structural proteins-like dystrophin), are
unknown. One possible explanation is that chronic and
regular rhythmical activity, combined with a specific fiber-type
distribution (an elevated combination of type-IIa and type-IIb),
could contribute to the more pronounced deleterious changes
observed for this muscle in vivo.
Clinical studies of FHL1 mutations provided evidence that
early onset and severity of muscle disease, especially in cases
of FHL1-dependent reducing body myopathy, could correlate
with progressive development and accumulation of
menadione-NBT positive ‘reducing bodies’ which contains
mutant FHL1 proteins. Reducing bodies are thought to be
aggresome-like cell inclusions that incorporate proteins of
various origins (10,11,19). In the present study, we reported
that loss of FHL1 function did not cause emergence of
menadione-NBT positive reducing bodies or electron-dense
protein aggregates in FHL1-null muscles, thus suggesting
that formation of reducing bodies in patients with FHL1 muta-
tions is likely due to a ‘gain of function’ of mutant FHL1.
Instead, we observed development and accumulation of
electron-lucent juxtanuclear inclusion bodies strongly resem-
bling membrane-limited autophagic vesicles in structure. We
speculate that accumulation of these autophagic vesicles
could be secondary to mechanisms of selective sequestration
and subsequent degradation of dysfunctional mitochondria
and other byproducts related to myofibrillar disassembly in
FHL1-null muscle fibers.
Our results also highlighted a crucial role for FHL1 in mouse
survival rates. The specific reasons associated for increased
mortality in FHL1-null mice are not known. In this study, we
presented evidence that skeletalmuscle remodeling is associated
with generalized muscle fatigue and age-dependent susceptibil-
ity to contraction-induced injury.Also,manifestation of lethargy
and lack of movement was regularly observed in older
FHL1-null mice (data not shown). Potential respiratory compli-
cations associated with impairment in sternohyoideus muscle
function could explain the observed decrease in survival rates
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in FHL1-null mice. However, it is important to note that
FHL1-null mice lack FHL1 expression in all organs, thus add-
itional systemic effects cannot be discarded. In a previous
study, we demonstrated that 8- to 10-week-old FHL1-null
mice exhibited a blunted and beneficial response to pressure
overload cardiac hypertrophy induced by transverse aortic con-
striction (21). Long-term echocardiographic assessment of
1-year-old FHL1-null mice further revealed the absence of
heart dysfunction in FHL1-null mice when compared with WT
littermate controls (data not shown). Thus, increased mortality
due to heart pump dysfunction is unlikely, although cardiac in-
volvement, including conduction defects, development of
arrhythmogenic events and hypertrophic cardiomyopathy are
observed in clinical cases of FHL1-dependent Emery–Dreifuss
muscular dystrophy, X-linked myopathy with postural muscle
atrophy, rigid spine syndrome and scapuloperoneal muscular
dystrophy (13–16,33,34). Interestingly, we observed the devel-
opment of a pelvic limb-clasping reflex that progressed to the
thoracic limbs with ageing in FHL1-null mice (not shown).
This reflex is generally observed in mice with brain lesions
(35), suggesting possible neuropathic complications in
FHL1-null mice.
In conclusion, thepresent studyprovides compelling evidence
that absence of FHL1 expression is sufficient to induce develop-
ment of an age-dependent myopathy associated with myofibril-
lar and intermyofibrillar disorganization inmice, suggesting that
‘loss of FHL1 function’ could lead to myopathy in patients with
FHL1 nonsense or frame-shift mutations. However, it should be
noted that the vast majority of mutations identified in patients
with FHL1 mutations are missense mutations or in-frame dele-
tions. In these cases, mutant phenotypes may result from
loss-of-function alone (FHL1 downregulation and impairment
of protein partner binding), or perhaps from simultaneous loss
of native FHL1 function and gain of function owing to aberrant
folding ofmutant FHL1 proteins.Misfolded protein can result in
protein aggregates/reducingbody formation,which is associated
with more severe disease manifestation in patients with FHL1
mutations. Production of mutant mouse models mimicking dif-
ferent FHL1 mutations, in addition to FHL1-null mutant mice,
will provide further insights intomolecularmechanisms relating
to FHL1 function and dysfunction in the clinical setting.
METHODS
Generation of FHL1-null mice and human muscle biopsies
We previously reported the generation of FHL1-null mice,
through a lacZ/neo knock-in strategy, resulting in loss of total
FHL1 protein in all tissues (21). Experiments were conducted
on1 and 5–6-month-oldmaleswithin a pureBlackSwiss back-
ground. Survival studies were collected for both male and female
mice over a period of 21months. Littermates for our experiments
were obtained by breeding WT (FHL1 +/y) Black Swiss males
and heterozygote (FHL1+/2) females, to produce 50%hemizy-
gote (FHL1 2/y) and 50%WT (FHL1 +/y) males. For our sur-
vival study, homozygote (FHL1 2/2) and heterozygote (FHL1
+/2) females were generated by crossing hemizygote (FHL1
2/y) males with heterozygote (FHL1 +/2) females. Offspring
from FHL1 intercrosses were genotyped by PCR analysis per-
formed on DNA extracted from ear clips. Specific primers
detecting FHL1 WT allele (forward, FW: 5′-ACCATGTCGG
AGAAGTTCGACT-3′; reverse, RV: 5′-AGGCTGCAGGTATA
CACCTGAA-3′) and FHL1 mutant allele (FW: 5′-CCTCTGAG
TCAGCAGCGTGATT-3′; RV: 5′-AGATGAAACGCCGAGT
TAACGC-3′) were used in standard semi-quantitative PCR pro-
cedures. The UCSD Animal Care and Use Committee approved
all animal procedures. The use of human skeletal muscle biopsy
samples was approved under the UCSDHumanResearch Protec-
tions Program Project number #121700XX.
Analysis of FHL1 mRNA expression
Total RNA was isolated from excised FHL1-null and WT skel-
etal muscles or cell culture preparations using Trizol reagent
(Life Technologies—Invitrogen) according to manufacturer’s
recommendations. First-strand cDNA synthesis from purified
RNAs and qPCR amplification were performed using the
GoTaq 2-Step RT-qPCR System kit (Promega) according to
manufacturer’s protocols. Resulting cDNAs were subjected to
SYBR Green-based real-time amplification using a C1000
Thermal Cycler apparatus (Bio-Rad). Each PCR amplification
reaction (20 ml volume) contained100 ngof starting cDNAtem-
plate and 0.5 mM of FW and RV primers. Cycling conditions for
SYBR Green primers consists of an initial step at 508C (2 min)
and a first denaturizing step at 958C (2 min), followed by 50
cycles of a thermal step protocol consisting of 958C (20 s),
608C(20 s) and728C(20 s).A standardmelt curve profiling con-
sisting of a 65–958C thermal ramp was performed at the end of
each protocol. Cycling conditions for FAM-based primers con-
sisted of a first denaturizing step at 958C (2 min), followed by 50
cycles of a thermal step protocol consisting of 958C (15 s) and
608C (1 min). Primers for FHL1 were designed using the
Primer3 software according to cDNA sequences of reference
(RefSeq) reported in GenBank (http://www.ncbi.nlm.nig.gov/)
and confirmed by independent cloning. Amplification of total
FHL1 was performed using a set of SYBR Green-based
primers spanning exons 3 and 4 (primer set P0). Amplification
of FHL1 splicing isoforms was performed using SYBR Green-
based primers recognizing distinct 5′ UTR regions (primer sets
P1, P2 and P3) or isoform-specific exon boundaries (primer
sets P4, P5 and P6) (Supplementary Material, Fig. S1): P0
(FW: 5′-CAACACCTGCGTGGACTG-3′; RV: 5′-CGTGCCA
GTAGCGATTCTTA-3′; 77 bp product), P1 (FW: 5′-GGTGC
CGCCTAGACAGCTGC-3′; RV: 5′-CAGTCGAACTTCTCC
GACAT-3′; 127 bp product), P2 (FW: 5′-CTGGGGTTGAG
GGAAGACAG-3′; RV: same as P1; 123 bp product) and P3
(FW: 5′-CCTGGGGCTCCAAGGTCCCT-3′; RV: same as P1;
127 bp product). The following primers were designed to
amplify with FAM-labeled TaqManw internal probes: P4 (FW:
5′-CTGCGTGGATTGCTACAAGA-3′; probe: 5′-TGTGCTG
GATGCAAGAACCCCA-3′; RV: 5′-CCTTCATAGGCCACC
ACACT-3′; 102 bp product); P5 (FW: same as P4; probe:
5′-TGTGCTGGATGCAAGAACCCCA-3′; RV: 5′-CACACT
GGGGACTTCCTAGC-3′; 126 bp product); P6 (FW: 5′-TGA
CTTGCCATGAGACCAAG-3′; probe: 5′-TGCAACAAGGG
TTTGGTAAAGGC-3′; RV: 5′-GCAACAAGGGTTTGGTAA
AGGC-3′; 100 bp product); beta-2-microglobulin (Life Tech-
nologies, product Mm00437762_m1). Absolute quantification
was calculated using the standard curve method where amplifi-
cation values were compared with a standard curve made of
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known concentrations of cloned and linearized plasmid-based
FHL1 cDNA sequences. Data reported inResult were calculated
as FHL1mRNAcopies permicrogramof total transcribedRNA.
Western blotting
Unless otherwise stated, proteins were extracted from tissue or
cells by briefly sonicating samples suspended in custom-made
RIPA buffer (1.752 g NaCl, 2 ml NP-40, 1 g deoxycholic acid,
1 ml 20% SDS, 6.67 ml 1.5 M Tris, pH 8, to 200 ml with
ddH2O), followed by 48C centrifugation (9838g, table-top cen-
trifuge with Eppendorf FA-45-24-11 rotor) to remove mem-
brane components. Protein samples were stored in
custom-made RIPA buffer at 2808C. 20 mg of total proteins
were separated using NuPAGE 4–12% Bis–Tris gels with
20× NuPAGEMESorMOPSSDSRunning buffers and antiox-
idants, according to manufacturer’s protocols (Novex—Life
Technologies). After separation, proteins were transferred to
nitrocellulose membrane in a Tris–Glycine buffer complemen-
tedwith20%methanol.Tovisualize bandsandcheck for transfer
efficiency, membranes were stained with Ponceau
S. Membranes were then blocked in a buffer containing 10 mM
Tris, 0.15 M NaCl, 0.1% Tween-20 and skim milk and rocked
with the primary antibody (1:500 to 1:1000 dilution) overnight
at 48C. After washing procedures, membranes were incubated
with peroxidase-conjugated secondary antibodies (1:1000 dilu-
tion) for 1 h at room temperature and bands identified using
chemiluminescence on autoradiography film. Bands were ana-
lyzed by densitometry and values expressed as arbitrary values of
protein levels, normalizedby total protein transferredonnitrocellu-
losemembrane (as visualizedwith Ponceau S). Primary antibodies
were used as follows: rabbit FHL1 targeting the 4th LIM domain
(Aviva—C-terminal region; ARP34378_T100), mouse FHL1
N-terminal region (abcam; ab58067), mouse MHC-I/slow
(Sigma;M8421, cloneNOQ7.5.4D), rabbit LC3B (Cell Signaling;
#3868, D11), mouse NDUFA9 (abcam/MitoSciences; ab14713/
MS111), mouse MT-CO1 (abcam/MitoSciences; ab14705/
MS404), mouse His-tag (Invitrogen; R931-25, clone 3D5), rabbit
histone H3 (Cell Signaling; #9717) and mouse sarcomeric
alpha-actinin/ACTN2 (Sigma; A7811, clone EA-53).
RNA-sequencing library construction and analysis
RNAsequencingwas performed as previously describedwith no
RNA or cDNA fragmentation and without any normalization
(36). RNA-sequencing libraries were constructed with random
hexamer priming. To reduce biological variation, RNA was
pooled from three biological replicates. Uniform amplification
of the cDNA library was achieved with amplification cycles
before the reaction reached saturation determined with qPCR.
Following sequencing, alignment of reads was performed with
Tophat (version 1.0.14) (24). Read-depth profiles were con-
structed with Tophat’s ‘wiggles’ tool and values were normal-
ized to total aligned reads and uploaded on the UCSC browser
(http://genome.ucsc.edu/index.html).
Subcellular fractionation and CS activity
Myofibrils were isolated frommouse sternohyoideus muscle by
homogenization in a glass dounce in 20 vol (w/v) of a borate–
KCl buffer (pH 7.1) containing 0.039 M sodium borate,
0.025 M KCl, 1 mM phenylmethylsulfonyl fluoride. The hom-
ogenate was centrifuged at 3200 rpm for 12 min, and the super-
natant was discarded. Purification of the pelleted material was
continued by washing twice with 1.0% Triton X-100 and by a
final suspension in 0.1 M KCl, 50 mM Tris (pH 7.4), and 1 mM
dithiothreitol (DTT). Before storage, they were washed in a
low-salt buffer containing 0.1 M KCl, 2 mM MgCl2, 0.01 M
Tris–maleate (pH7.0), 50%glycerol, and 1 mMDTT.All proce-
dures were performed at 48C. To isolate nuclei and mitochon-
drial fractions, muscles were homogenized in a glass dounce in
buffer containing 10 mM Tris (pH 7.4), 250 mM sucrose, 1 mM
EDTA, 0.15% Nonidet P-40, 10 mM sodium butyrate, 0.1 mM
phenylmethylsulfonyl fluoride, protease inhibitor mixture
(Roche) and phosphatase inhibitors (Roche). Subcellular frac-
tionation was carried out by centrifugation at 600g to pellet
crude nuclear fraction.The crudenuclear pelletwas resuspended
in homogenization buffer, layered on a 2 M sucrose pad and cen-
trifuged at 7500g for 5 min to isolate the enriched nuclear frac-
tion. The first supernatant from the crude nuclear pellet was
centrifuged at 5000g for 30 min to yield the mitochondria,
which were further purified using a 28% Percoll gradient and
14 000g spin for 40 min (mitochondria are in the pellet). All
stepswere carried out at 48C. The purity of these individual frac-
tions was evaluated by western blotting of specific fraction
markers, namely histone H3 for the nuclear fraction, NDUFA9
for the mitochondrial fraction and muscle alpha-actinin for the
myofibrillar fraction. Western blot analysis was also performed
to test expression of FHL1 proteins in isolated subcellular frac-
tions and in unfractionated samples. Living mitochondria pre-
parations for CS activity measurements were obtained using
the Mitochondria Isolation Kit MITOISO1 (Sigma). Activity
was determined in triplicate based on the formation of 2-nitro-
5-thiobenzoic acid (TNB) at a wavelength of 412 nm at 258C
on a spectrophotometer plate reader (SpectraMax 340 PC). In
each well, 8 ml of sample was added to a reaction medium con-
taining 178 ml assay buffer, 2 ml of 30 mM acetyl coenzyme A
and 10 mM TNB acid. The baseline assay solution absorbance
was recorded, reactions were initiated by addition of 10 ml oxa-
loacetic acid, and the change in absorbance measured every 15 s
for 2 min.
LC–MS/MS
Snap frozen soleus and TA muscle samples were ground into a
fin powder using a mortar and pestle and immersed in 8
volumes of freshly prepared lysis buffer (8 Murea, 10 mMdithio-
threitol DTT solution) and vortexed until complete dissolution.
Muscle homogenates were centrifuged at 15 000g for 20 min
at 48C to remove any insoluble materials and fully solubilized
samples were stored at 2808C until analysis. 100 mg aliquots
of protein samples were adjusted to 200 ml with 4 M urea and
then reducedandalkylated by triethylphosphine and iodoethanol
as previously described (37). A 150 ml aliquot of a 20 mg/ml
trypsin solution was added to the sample and incubated at
358C for 3 h, after which another 150 ml of trypsin was added,
and the solution incubated at 358C for 3 h. Exactly 20 mg of
each tryptic digest sample were injected randomly as two tech-
nical replicates onto a C18 reversed-phase column (TSK gel
ODS-100V, 3 mm, 1.0 × 150 mm) at a flow rate of 50 ml/min
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as part of the Surveyor autosampler and MS HPLC system
(Thermo-Electron, Waltham, MA, USA) coupled to a Thermo-
Finnigan linear ion-trap mass spectrometer. The mobile phases
A, B and C were 0.1% formic acid in water, 50% ACN with
0.1% formic acid in water and 80% ACN with 0.1% formic
acid in water, respectively. The gradient elution profile was as
follows: 10% B (90% A) for 7 min, 10–67.1% B (90–32.9%
A) for 163 min, 67.1–100% B (32.9–0% A) for 10 min and
100–50% B (0–50% C) for 10 min. Data were collected in the
‘data-dependentMS/MS’modewith theESI interface using nor-
malized collision energy of 35%. Dynamic exclusion settings
were set to repeat count 1, repeat duration 30 s, exclusion dur-
ation 120 s and exclusion mass width 0.6 m/z (low) and 1.6 m/z
(high). Acquired data were searched against the most recent
UniProt protein sequence database of mouse using SEQUEST
(v.28 rev.12) algorithms in Bioworks (v.3.3). General para-
meters were set to: mass type set as ‘monoisotopic precursor
and fragments’, enzyme set as ‘trypsin (KR)’, enzyme limits
set as ‘fully enzymatic—cleaves at both ends’, missed cleavage
sites set at 2, peptide tolerance 2.0 amu, fragment ion tolerance
1.0 amu, fixed modification set as +44 Da on Cysteine and no
variable modifications used. The searched peptides and proteins
were validated by PeptideProphet and ProteinProphet in the
Trans-Proteomic Pipeline (v.3.3.0) (http://tools.proteom
ecenter.org/software.php). Only proteins with probability
≥0.9 and peptides with probability ≥0.8were used for quantita-
tion, which was performed using IdentiQuantXLTM software as
previously described (38). One-way analysis of variance
(ANOVA) was performed to determine the significance of dif-
ferences between the two groups (WT versus FHL1 null) for
each muscle type. A P-value ≤ 0.05 was considered for signifi-
cantly different protein expression between groups.
Measurement of fiber-type distributions
The distribution of fiber types was determined by separating
MHC isoforms using SDS–PAGE as previously described
(39). Muscles were homogenized and centrifuged, and the
myofibril-rich pellets were washed and resuspended in buffers
supplemented with protease inhibitor cocktail (Roche). Protein
was then diluted in sample buffer (2% SDS, 80 mM Tris, 10%
glycerol and 1.2% (wt/vol) bromophenol blue) containing
100 mM DTT as a reducing agent to a concentration of
0.125 mg/ml proteins and boiled for 5 min. Isoforms were sepa-
rated on polyacrylamide gels (16 × 22 cm, thickness ¼
0.75 mm) for 22 h at 275 V at 48C. Stacking and resolving gels
were 4 and 8% polyacrylamide, respectively. Gels were silver-
stained according to the manufacturer’s protocol (SilverQuest
Staining Kit, Invitrogen). Densitometry was performed to quan-
tify bands and compute isoforms distribution. Data in Results
were expressed as percentage (%) of the total amount of MHC
detected.
Histology and immunohistochemistry
Excisedmuscle tissueswere snap frozen in isopentane precooled
in liquid nitrogen and stored at 2808C until further analysis.
Transversely or longitudinally oriented sections (8 mm) were
cut at mid point and stained according to published protocols
and procedures (40). Standard histochemical stains
includedhematoxylin and eosin (H&E),NADH-TR,Congo-red,
Gomori trichrome (Go-Tri) and Menadione-NBT staining.
Whole histological sections were imaged and recorded with a
digital slide scanner Hamamatsu NanoZoomer 2.0-HT and ana-
lyzed with the ImageJ software package. H&E transversal sec-
tions were assessed for the number of fibers containing central
nuclei over the total number of fibers counted per field images
taken at 15× magnification. On average, 300 fibers were
counted per field (two separated fields per section, one section
per limb, four animals per group;, i.e. N ¼ 16 fields per group).
Immunodetection was performed on 8 mm cryosections fixed
in 2208C acetone for 10 min and blocked in serum for at least
8 h at 48C. Primary antibodies were applied overnight at 48C
(1:100–1:200 dilutions). Sections were then stained with sec-
ondary antibodies at room temperature for 1 h (Invitrogen;
1:100–1:300 dilution). Sections requiring fluorescent detection
were visualized under an epifluorescent microscope (Olympus
IX70) and deconvolved using the SoftworX analysis package.
Ultrastructural analysis (TEM)
Muscle segments were first fixed in 4% paraformaldehyde in
0.1 M sodium cacodylate (SC) buffer (pH 7.3) and then moved
into 2% glutaraldehyde in 0.1 M SC buffer for 24 h and rinsed
three times in 0.1 M SC buffer.Muscle segments were post-fixed
and stained with 1% osmium tetroxide (OsO4) and 1.5% potas-
sium ferrocyanide (K4Fe(CN)6) in 0.1 M SC buffer for 90 min
at 48C. The use of reduced osmium tetroxide-containing potas-
sium ferrocyanide favored a high electron density of glycogen
particles (41). After postfixation, samples were rinsed three
times in 0.1 M SC buffer at 48C followed by a final rinse in
ddH2O and dehydrated through graded series of alcohol at 4–
208C. Samples were then immersed two times 10 min in
acetone, followed by a 50:50 mixture of acetone and epoxy
resin Durcupan (Sigma-Aldrich) for 2 h on shaker and finally
in a 100% epoxy resin Durcupan solution changed every 24 h
for up to 3 days on shaker. Samples were sectioned at 60 nm
on a Leica UCT ultramicrotome, and picked up on Formvar
and carbon-coated copper grids. Sections were stained with
2% uranyl acetate for 5 min and Sato’s lead stain for 1 min.
Grids were viewed using a JEOL 1200EX II (JEOL, Peabody,
MA, USA) transmission electron microscope and photographed
using a Gatan digital camera (Gatan, Pleasanton, CA, USA) at
different magnifications.
Isometric stress measurements
The model used for biomechanical testing was the 5th toe belly
of the multibellied EDL. This belly was selected for its fiber
length homogeneity, fiber-type heterogeneity and robust origin
and insertion tendons (42). After mouse sacrifice, hindlimbs
were transected at the proximal femur, skinned and immersed
in ice-cold mammalian Ringer solution. The 5th toe belly of
the EDL was excised and transferred to a custom-made muscle-
testing apparatus (42). The distal tendonwas tied downwith silk
sutures to a rigid post interfaced with dual-mode ergometer
(Aurora Scientific, Aurora, ON, Canada). The proximal tendon
was secured, also with silk sutures, to a rigid frame attached to
a horizontally adjustable platform. Muscle length (Lm) was
adjusted such that mechanical slack was eliminated, and laser
222 Human Molecular Genetics, 2014, Vol. 23, No. 1
diffraction verified slack sarcomere length (3.0 mm). Lm was
then measured through a dissecting microscope fitted with an
eyepiece crosshair reticule, by using a digital micrometer to
translate the chamber under the field of view from the proximal
EDL origin to the distal myotendinous junction. An electrical
stimulator (FHC, Bowdoinham,ME, USA) providedmuscle ac-
tivation via platinumplate electrodes extending across the entire
muscle. Muscle twitches were imposed at successively higher
stimulation voltages, beginning with 5 V, until maximum
twitch force was achieved (typically at 8 V). Voltage was
then doubled to guarantee recruitment of all fibers. Maximum
isometric force was imposed by applying a 400 ms train of
0.3 ms pulses delivered at 100 Hz while maintaining constant
muscle length. A computer algorithm in LabVIEW (National
Instruments, Austin, TX, USA) was used to trigger the stimula-
tor, acquire signals from the force transducer and analyze all
force-time records. Three contractions were imposed, each
spaced 2 min apart and successive isometric force values were
averaged. After testing, the muscle was removed from the
chamber and weighed. To determine the longitudinal stress
within themuscle, forcewas normalized toPCSA, an anatomical
parameter whose value is directly proportional to force-
generating capacity. Fiber length (Lf in mm) was determined
for each muscle by multiplying Lm by the characteristic 5th toe
EDL Lf:Lm ratio of 0.69. Muscle mass (M in mg), muscle
density (r ¼ 1.056 g/cm3), fiber pennation angle (u ¼ 11.38),
and Lf were used to compute PCSA (in mm
2), which is equal
to (M cos u)/(rLf). The constants in this formula have been pub-
lished previously (43).
Mouse exercise protocol
Four pairs of 1-year-old FHL1-null and WT male littermates
were subjected to a single round of treadmill running protocol
(Model: exer-6M Treadmill with Treadmill Shock Detection
Unit). Mice were placed in their respective lanes and allowed
to adjust to the surroundings for 15 min. During the adjustment
period, the treadmill was set to 0.09 m/s. The treadmill incline
was set to 258 at all times. Every 2 min, the speed of the treadmill
was ramped up in 0.03 m/s steps from the initial 0.09 m/s. Mice
were left running until exhaustion, defined as inability to con-
tinue running despite a mild electrical stimulation provided by
an electro shocking device.
Satellite cell isolation, culture, transfection
and differentiation
Satellite cell-derived primary myoblasts were isolated from
soleus muscles by dissection and sequential digestions in Col-
lagenase B – Dispase II solution (Roche) at 378C, as previously
published (44). Myoblasts were separated from non-myogenic
cells by two rounds of differential plating of 1 h each. Enriched
myoblast populationswere plated at a density of 0.1 × 106 cells/
cm2 on gelatin-coated wells and cultured in complete medium
containing Ham’s F-10 (Cellgro) supplemented with
L-glutamine, 20% FBS (Life Technologies), 10 mg/ml strepto-
mycin, 100 units/ml penicillin (GIBCO) and 2.5 ng/ml bFGF
(Life Technologies). Proliferating myoblasts were grown to
70% confluency and further purified by one additional round
of differential plating. Cells were passaged at least two to three
times before being used for experimental procedures.
Differentiationofmyoblastswas achievedby replacing the high-
serum medium with one containing DMED (Cellgro) supple-
mented with L-glutamine, 5% horse serum (Life Technologies),
10 mg/ml streptomycin and 100 units/ml penicillin (GIBCO).
Myoblast transfections were performed with the pcDNA6/
V5-His vector (Invitrogen), containing ampicillin and blastici-
din selection cassettes. In this vector, FHL1 constructs were
conjugated to a V5-His sequence tag at the cDNA 3′ end.
TransIT-2020 transfection reagent (Mirus) was used to transfect
the pCDNA constructs to proliferatingmyoblasts in their50%
confluency, according to manufacturer’s recommendations.
Twenty-four hours post-transfection, myoblasts underwent
blasticidin-mediated selection. After 1 week of blasticidin ex-
posure, surviving myoblasts colonies were tested for FHL1
isoform expression.
Measurements of myoblast fusion indexes
The fusion index was defined as the total number of nuclei
(excluding mono- and binucleated) in alpha-actinin positive
cells divided by the total number of nuclei per field. The
number of nuclei per myotube was established by counting
nuclei within every myotube per microscopic field divided by
the number of myotubes in the field, where a myotube is
defined as an alpha-actinin positive cellwith at least three nuclei.
STATISTICS
Results were expressed as mean+SEM unless otherwise indi-
cated; one-way and two-way ANOVAs were applied to test for
differences (P , 0.05) between age-matched FHL1-null and
WT groups. When statistical significance was achieved, post
hoc analysis using Tukey’s t-test with the Bonferroni correction
was applied.
SUPPLEMENTARYMATERIAL
Supplementary Material is available at HMG online.
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